Alectinib

Lung Cancer

Joshua PalmerSmall moleculePhase 4 / ApprovedActive

B

61/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 58/ 100
Competitive Position: 65/ 100

Competitive context

298 Active assets in the Lung Cancer cohort.

Asset / Sponsor	Phase	Rating
Cis-Diamminedichloroplatinum Ii University of Vermont	Phase 4	BB
Carboplatin SystImmune Inc.	Phase 4	BB
Desflurane Peter MacCallum Cancer Centre, Australia	Phase 4	BB
Etoposide SystImmune Inc.	Phase 3	BB
Nivolumab University of Chicago	Phase 4	BB

View all 50 →

Same molecule, other indications

Alectinib is also rated in:

non-small cell lung carcinomaActive

BB

Indicative · Phase 4

66 / 100

anaplastic large cell lymphomaActive

B

Indicative · Phase 2/3

63 / 100

hematopoietic and lymphoid system neoplasmActive

B

Indicative · Phase 2/3

62 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.